
Opinion|Videos|January 31, 2025
PERSEUS Trial Highlights: Dara-VRd vs VRd in Transplant-Eligible NDMM
Panelists discuss how the PERSEUS trial demonstrated superior progression-free survival with daratumumab-VRd compared to VRd alone in patients with transplant-eligible newly diagnosed multiple myeloma (NDMM), potentially establishing a new standard of care in this setting.
Episodes in this series






































